Search results
Order by most recent / most popular / relevance
Results: 1-10 of 197
Prohibition not granted as non-infringement allegation held justified
- Borden Ladner Gervais LLP
- -
- Canada
- -
- July 18 2012
The Court heard this application and the next application consecutively and issued decisions on the same day, however, indicated that each was considered separately
Teva Canada Innovation v. Attorney General of Canada
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 8 2013
The Patented Medicine Prices Review Board (the PMPRB) ordered Teva to pay the Crown approximately $2.4 million for selling its product at an
Compound patent found valid in face of allegations of lack of utilitysound prediction and insufficiency
- Borden Ladner Gervais LLP
- -
- Canada
- -
- February 27 2013
Apotex and Novopharm started actions to impeach Novartis’ patent covering the compound imatinib, sold under the brand name GLEEVEC. They then sent
Definition of “innovative drug” does not include variations
- Borden Ladner Gervais LLP
- -
- Canada
- -
- January 23 2013
This is an appeal by Takeda of a decision of the Court, in which the Court upheld the decision of the Minister of Health to refuse to list Takeda’s
Documents included in joint book for trial should be exhibits for appeal
- Borden Ladner Gervais LLP
- -
- Canada
- -
- June 11 2012
The issue to be determined relates to the contents of the appeal books
Intellectual property weekly abstracts bulletin
- Borden Ladner Gervais LLP
- -
- Canada
- -
- April 1 2013
The Court granted a Prohibition Order to AstraZeneca, preventing Ranbaxy from entering the market with a generic version of ompeprazole until the
Patent found valid and infringed - accounting of profits awarded
- Borden Ladner Gervais LLP
- -
- Canada
- -
- March 18 2013
Apotex sued for impeachment of Lundbeck’s patent. Lundbeck counterclaimed for infringement. The Court held that the patent was valid and infringed
Listing of patent on patent register against combination drug refused
- Borden Ladner Gervais LLP
- -
- Canada
- -
- October 16 2012
COMPLERA contains three medicinal ingredients
Only authorized correspondent can pay maintenance fees for application
- Borden Ladner Gervais LLP
- -
- Canada
- -
- November 14 2011
The Judge found that the acceptance of maintenance fees paid within the grace period by someone other than the authorized correspondent reinstated a lapsed patent application, but the subsequent reimbursement of those fees nullified the reinstatement
Patent application rejected again for obviousness
- Borden Ladner Gervais LLP
- -
- Canada
- -
- May 28 2012
The Commissioner had previously refused the patent application on the basis of obviousness
Current Search
- Author - Beverley Moore
- Workarea - Patents